Semaglutide Alleviates Metabolic-Linked Liver Disease in People With HIV
By Elana Gotkine HealthDay Reporter
TUESDAY, April 30, 2024 -- For people with HIV (PWH), semaglutide is effective for metabolic dysfunction-associated steatotic liver disease (MASLD), according to a research letter published online April 30 in the Annals of Internal Medicine.
Jordan E. Lake, M.D., from UTHealth Houston, and colleagues designed a pilot study to examine the effect of semaglutide on magnetic resonance imaging-proton density fat fraction-quantified intrahepatic triglycerides (IHTG) in PWH and MASLD. Eligible participants were aged 18 years or older and had suppressed HIV-1 RNA while using antiretroviral therapy. The per-protocol analysis included 49 of 51 participants with central adiposity, insulin resistance or prediabetes, and steatotic liver disease.
The researchers observed clinically significant reductions in IHTG over 24 weeks. Overall, 29 and 58 percent of participants had complete resolution of MASLD and a relative reduction of IHTG of at least 30 percent, respectively. Anthropometric measurements, glucose regulation markers, and triglyceride concentrations also improved significantly. Semaglutide 1 mg weekly was tolerated by all participants. Grade 1 gastrointestinal symptoms were the most common adverse events.
"In summary, semaglutide, 1 mg weekly, is an effective therapy for MASLD in PWH and shows evidence of broader cardiometabolic benefit," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Small but Important Differences Seen Between Rosuvastatin, Atorvastatin
WEDNESDAY, Oct. 30, 2024 -- There are small but important differences in risk for some clinical outcomes associated with rosuvastatin and atorvastatin, according to a study...
Referral to Hepatology Low With Excessive Alcohol Use, High FIB-4
MONDAY, Oct. 7, 2024 -- Only 37 percent of patients with excessive alcohol use (EAU) and a high fibrosis-4 index (FIB-4) are referred to hepatology, according to a study published...
GLP-1 RA Use Linked to Reduced Cirrhosis Risk in MASLD, Diabetes
TUESDAY, Sept. 17, 2024 -- For patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) use...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.